Nov 3, 8:09 AM ET
Alkermes reported third-quarter 2026 results on November 3, 2026. Total revenues rose to $480.1 million from $394.2 million a year earlier, but GAAP net income fell to $16.3 million from $82.8 million, and results included $29.8 million of costs related to the Avadel acquisition. The company reiterated its 2026 expectations, which call for total revenues of $1.73 billion to $1.84 billion and a GAAP net loss of $95 million to $115 million.
- Q3 2026 total revenues were $480.1 million versus $394.2 million in Q3 2025; diluted EPS was $0.09 versus $0.49.
- Q3 2026 Adjusted EBITDA was $120.1 million, compared with $121.5 million in Q3 2025.
- Nine-month GAAP net loss was $49.7 million, compared with GAAP net income of $192.3 million in the same period of 2025.
- 2026 expectations were reiterated, including a GAAP net loss of $95 million to $115 million and Adjusted EBITDA of $370 million to $410 million.
Read the filing on SEC.gov ↗
Sep 16, 9:12 AM ET
Alkermes plc expanded its Board from ten to eleven directors and appointed Anne C. Whitaker, effective immediately, with a term expiring at the 2027 annual general meeting. The filing says she has not yet been named to any board committee, and her initial director equity award has a target value of $600,000.
- Board size increased from 10 to 11 directors; Whitaker appointed effective immediately, with term expiring at the 2027 annual general meeting
- Initial new director equity award has an aggregate target value of $600,000, split 50% stock options and 50% restricted stock units
- Award expected to be granted in October 2026 and to vest in three equal annual installments starting on the first anniversary of the grant date
- Company entered into an indemnification deed and Alkermes, Inc. entered into an indemnification agreement with Whitaker
Read the filing on SEC.gov ↗
Aug 12, 9:26 AM ET
Alkermes plc entered into Amendment No. 1 to its credit agreement dated February 12, 2026, with JPMorgan Chase Bank as administrative agent. The amendment lowers the interest rate spread by 0.75% on the term loan A facility and by 0.50% on the term loan B facility, among other changes. The filing does not report earnings or other operating results, so its direct effect on shareholders is limited to lower borrowing costs on the company's term loans.
- Term loan A outstanding principal: $745,312,500, maturing February 12, 2031
- Term loan B outstanding principal: $773,062,500, maturing August 12, 2031
- Spread reduced 0.75% on term loan A and 0.50% on term loan B
- Amendment dated August 12, 2026, filed as Exhibit 10.1
Read the filing on SEC.gov ↗
Jul 28, 7:05 AM ET
Alkermes reported second-quarter 2026 revenue of $496.0 million, up from $390.7 million a year earlier, driven by its commercial products and LUMRYZ following the Avadel acquisition. GAAP net income fell to $0.5 million from $87.1 million, and the company widened its 2026 GAAP net loss outlook to ($95) to ($115) million and cut its EBITDA outlook, while keeping revenue and Adjusted EBITDA expectations unchanged. Blair Jackson will become chief executive on August 1, 2026, succeeding Richard Pops, who remains chairman.
- Q2 2026 total revenues were $496.0 million versus $390.7 million in Q2 2025; GAAP net income was $0.5 million versus $87.1 million.
- Adjusted EBITDA was $139.2 million for the quarter, up from $126.5 million, and six-month GAAP net loss was $66.0 million.
- 2026 GAAP net loss expectation widened to ($95) to ($115) million from ($70) to ($90) million; EBITDA cut to $75 to $95 million from $105 to $135 million.
- 2026 total revenue ($1,730 to $1,840 million) and Adjusted EBITDA ($370 to $410 million) expectations were unchanged.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.